World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: TCTR
Last refreshed on: 4 March 2024
Main ID:  TCTR20141011001
Date of registration: 11/10/2014
Prospective Registration: No
Primary sponsor: Ratchadapiseksompotch Fund
Public title: Factors related with prostaglandin associated periorbitopathy (PAP) in glaucoma patients
Scientific title: Factors related with prostaglandin associated periorbitopathy (PAP) in glaucoma patients
Date of first enrolment: 19/06/2014
Target sample size: 150
Recruitment status: Recruiting
URL:  https://www.thaiclinicaltrials.org/show/TCTR20141011001
Study type:  Observational
Study design:  N/A  
Phase:  N/A
Countries of recruitment
Thailand
Contacts
Name: Chanikarn    Patradul
Address:  43/1 Panuvilla, Sirinthorn soi9, Sirinthorn road, Bangbumru, Bangplat 10700 Bangkok Thailand
Telephone: 0818678167
Email: c.patradul@gmail.com
Affiliation:  Faculty of Medicine, Chulalongkorn University
Name: Chanikarn    Patradul
Address:  43/1 Panuvilla, Sirinthorn soi9, Sirinthorn road, Bangbumru, Bangplat 10700 Bangkok Thailand
Telephone: 0818678167
Email: c.patradul@gmail.com
Affiliation:  Faculty of Medicine, Chulalongkorn University
Key inclusion & exclusion criteria
Inclusion criteria: Glaucoma or ocular hypertension patients
Use prostaglandin analogs for controlling IOP
Continue using for at least 3 months

Exclusion criteria: Patients who have history of intraocular or extraocular surgery except cataract, filtering surgery, and laser treatment
Patients who use other glaucoma drugs other than PGAs except timolol within 6 months
Patients who have generalized lipodystrophy


Age minimum: 18 Years
Age maximum: 0 N/A (No limit)
Gender: Both
Health Condition(s) or Problem(s) studied
prostaglandin associated periorbitopathy
glaucoma
ocular hypertension
risk factors
protective factors
prostaglandin associated periorbitopathy glaucoma ocular hypertension
prostaglandin associated periorbitopathy
glaucoma
ocular hypertension
risk factors
protective factors
Intervention(s)
Glaucoma or ocular hypertension patients who use Prostaglandin eyedrops
prostaglandin eyedrops users
Treatment
Primary Outcome(s)
Risk factors and protective factors none Photographs
Secondary Outcome(s)
Prevalence none none
Secondary ID(s)
Source(s) of Monetary Support
Ratchadapiseksompotch Fund
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed: 30/04/2015
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history